Among prospective trials, the BILCAP study demonstrated a survival benefit of adjuvant capecitabine over observation in patients with biliary tract cancer (BTC) in the per‐protocol analysis, although the primary intention‐to‐treat analysis did not reach statistical significance [ 6 ].
← all excerpts
Potential Survival Benefit of Adjuvant Chemotherapy in Stage IV Intrahepatic Cholangiocarcinoma: A Multicenter, Stage-Stratified Analysis.
2
—
—
The sentences
Lymph node metastasis showed a trend toward worse survival but did not reach statistical significance (HR 1.704, 95% CI 0.976–2.975, p = 0.061).